8.56
+0.18(+2.15%)
Currency In USD
| Previous Close | 8.38 |
| Open | 8.4 |
| Day High | 8.62 |
| Day Low | 8.35 |
| 52-Week High | 11.31 |
| 52-Week Low | 6.02 |
| Volume | 2.14M |
| Average Volume | 3.38M |
| Market Cap | 1.8B |
| PE | -47.56 |
| EPS | -0.18 |
| Moving Average 50 Days | 8.86 |
| Moving Average 200 Days | 8.44 |
| Change | 0.18 |
If you invested $1000 in BioCryst Pharmaceuticals, Inc. (BCRX) 10 years ago, it would be worth $751.54 as of August 24, 2025 at a share price of $8.56. Whereas If you bought $1000 worth of BioCryst Pharmaceuticals, Inc. (BCRX) shares 5 years ago, it would be worth $2,156.17 as of August 24, 2025 at a share price of $8.56.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioCryst Announces Departure of Dr. Helen Thackray
GlobeNewswire Inc.
Aug 11, 2025 11:00 AM GMT
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition i
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
GlobeNewswire Inc.
Jul 31, 2025 11:00 AM GMT
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to re
BioCryst to Report Second Quarter 2025 Financial Results on August 4
GlobeNewswire Inc.
Jul 21, 2025 11:00 AM GMT
RESEARCH TRIANGLE PARK, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2025 financial results on Monday, August 4, 2025. BioCryst management will